D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.D609 acts by inducing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). D609 acts by causing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS).

PC-PLC:6.4 μM (Ki)

D609 (100 μM; 2 hours) significantly inhibits the proliferation of various cell lines[2].At concentrations of 50, 100, and 200 μM (2 hours), D609 activates caspase-3 at 200 μM, while at 50 and 100 μM, no detectable cleavage is observed[2].D609 (100 μM; 2 hours) markedly inhibits BrdU incorporation in BV-2 microglial cells, leading to G1 phase cell accumulation and a decrease in the number of cells in the S phase[2].D609 (100 μM; 2 hours, followed by 2 or 22 hours of cultivation without D609) increases ceramide levels, upregulates p21 expression, and results in decreased phosphorylation of Rb[4].

D609 (2.5 and 10 mg/kg/day; intraperitoneal injection; continuous for 6 weeks) inhibits the progression of pre-existing atherosclerotic lesions in apoE-/- mice and transforms the lesion composition into a more stable phenotype[3].Pre-treatment with D609 (50 mg/kg; intraperitoneal injection; single dose) 30 minutes before intratracheal administration of LPS (3 mg/kg) prevents lipopolysaccharide-induced pulmonary arterial hypertension in adult male Wistar rats[2].